{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:52:55Z","timestamp":1783975975390,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although less virulent than Pseudomonas aeruginosa, non-aeruginosa Pseudomonas (NAP) are opportunistic pathogens that cause invasive infections, mainly in immunosuppressed or intensive care patients. MDR strains of NAP are increasingly isolated, especially MBL-producing isolates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We evaluated the activity of cefiderocol, ceftazidime\/avibactam and ceftolozane\/tazobactam against a collection of clinical isolates of NAP, which was voluntarily enriched with resistant strains.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively determined the MICs of cefiderocol, ceftazidime\/avibactam and ceftolozane\/tazobactam in 71 NAP clinical isolates. Most isolates of our collection were not susceptible to meropenem (75%) or ceftazidime (45%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the first-line \u03b2-lactam\u2013resistant isolates, the strains for which no carbapenemase was detected were susceptible to ceftolozane\/tazobactam or ceftazidime\/avibactam, except for one isolate. These latter associations were more active against P. fluorescens isolates than against other NAP. Most isolates (94%) of our collection were susceptible to cefiderocol, with a median MIC of 0.25\u2005mg\/L. In particular, the 19 carbapenemase-producing strains, including 15 VIM-producing strains, were susceptible to cefiderocol. Cefiderocol MICs were higher for P. fluorescens complex isolates (MIC50\u200a=\u200a2\u2005mg\/L) than for P. putida complex isolates (MIC50\u200a=\u200a0.25\u2005mg\/L). Resistance to cefiderocol was detected in only four isolates, of which three P. fluorescens complex isolates remained susceptible to ceftolozane\/tazobactam and ceftazidime\/avibactam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftolozane\/tazobactam and ceftazidime\/avibactam may be of interest as second-line \u03b2-lactams against non\u2013carbapenemase-producing strains. Cefiderocol was highly active against NAP of our collection, especially MBL-producing isolates. Further studies are needed to correlate in vitro susceptibility of NAP to cefiderocol and clinical responses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf067","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:51:22Z","timestamp":1742298682000},"page":"1296-1301","source":"Crossref","is-referenced-by-count":4,"title":["<i>In vitro<\/i> activity of ceftolozane\/tazobactam, ceftazidime\/avibactam and cefiderocol against clinical isolates of non-<i>aeruginosa Pseudomonas<\/i>"],"prefix":"10.1093","volume":"80","author":[{"given":"Lucie","family":"Thene","sequence":"first","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU de Toulouse, Universit\u00e9 de Toulouse Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Floch","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU de Toulouse, Universit\u00e9 de Toulouse Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille V","family":"Chagneau","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU de Toulouse, Universit\u00e9 de Toulouse Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-8700","authenticated-orcid":false,"given":"Damien","family":"Dubois","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU de Toulouse, Universit\u00e9 de Toulouse Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Massip","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU de Toulouse, Universit\u00e9 de Toulouse Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2025050205522366100_dkaf067-B1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1128\/CMR.00044-14","article-title":"Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans","volume":"27","author":"Scales","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2025050205522366100_dkaf067-B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijid.2024.01.007","article-title":"Pseudomonas fluorescens pneumonia","volume":"140","author":"Ishii","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025050205522366100_dkaf067-B3","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/antibiotics12040670","article-title":"Pseudomonas bacteremia in a tertiary hospital and factors associated with mortality","volume":"12","author":"Ioannou","year":"2023","journal-title":"Antibiotics"},{"key":"2025050205522366100_dkaf067-B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13756-024-01390-9","article-title":"Pseudomonas fluorescens CRBSI outbreak: complying with the standardization of invasive procedures is a step ahead in the fight against antimicrobial resistance","volume":"13","author":"Volkow","year":"2024","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025050205522366100_dkaf067-B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fmed.2017.00183","article-title":"Infections caused by antimicrobial drug-resistant saprophytic gram-negative bacteria in the environment","volume":"4","author":"Raphael","year":"2017","journal-title":"Front Med"},{"key":"2025050205522366100_dkaf067-B6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/mdr.2017.0257","article-title":"Molecular characterization of Pseudomonas putida group isolates carrying blaVIM-2 disseminated in a university hospital in Korea","volume":"24","author":"Hong","year":"2018","journal-title":"Microb Drug Resist"},{"key":"2025050205522366100_dkaf067-B7","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.micpath.2024.106668","article-title":"Emergence of aztreonam\/avibactam and tigecycline-resistant Pseudomonas putida group co-producing blaIMP-1, blaAFM-4 and blaOXA-1041 with a novel sequence type ST268 in Southwestern China","volume":"192","author":"Jian","year":"2024","journal-title":"Microbial Pathogenesis"},{"key":"2025050205522366100_dkaf067-B8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/jac\/dkp491","article-title":"Metallo-\u03b2-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones","volume":"65","author":"Juan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025050205522366100_dkaf067-B9","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.12998\/wjcc.v12.i12.2099","article-title":"Thoracic spine infection caused by Pseudomonas fluorescens: a case report and review of literature","volume":"12","author":"Li","year":"2024","journal-title":"World J Clin Cases"},{"key":"2025050205522366100_dkaf067-B10","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2147\/IDR.S366567","article-title":"First identification of a multidrug-resistant Pseudomonas putida co-carrying five \u03b2-lactam resistance genes recovered from a urinary tract infection in China","volume":"15","author":"Bao","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025050205522366100_dkaf067-B11","author":"EUCAST"},{"key":"2025050205522366100_dkaf067-B12","author":"EUCAST"},{"key":"2025050205522366100_dkaf067-B13","doi-asserted-by":"publisher","first-page":"ofab617","DOI":"10.1093\/ofid\/ofab617","article-title":"Multicenter, prospective validation of a phenotypic algorithm to guide carbapenemase testing in carbapenem-resistant Pseudomonas aeruginosa using the ERACE-PA global surveillance program","volume":"9","author":"Gill","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025050205522366100_dkaf067-B14","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1128\/JCM.01299-13","article-title":"A convenient method to screen for carbapenemase-producing Pseudomonas aeruginosa","volume":"51","author":"Fournier","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2025050205522366100_dkaf067-B15","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/JCM.02585-10","article-title":"Strain-tailored double-disk synergy test detects extended-spectrum oxacillinases in Pseudomonas aeruginosa","volume":"49","author":"Hocquet","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2025050205522366100_dkaf067-B16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1128\/JCM.02313-12","article-title":"Clonal dissemination of Pseudomonas aeruginosa isolates producing extended-spectrum \u03b2-lactamase SHV-2a","volume":"51","author":"Jeannot","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2025050205522366100_dkaf067-B17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijantimicag.2016.09.012","article-title":"High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations","volume":"48","author":"Chalhoub","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205522366100_dkaf067-B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025050205522366100_dkaf067-B19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025050205522366100_dkaf067-B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2025050205522366100_dkaf067-B21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/antibiotics13090874","article-title":"Cefiderocol for the treatment of infections by VIM-type-producing gram-negative bacteria","volume":"13","author":"Kirkegaard-Biosca","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025050205522366100_dkaf067-B22","doi-asserted-by":"publisher","first-page":"ofab311","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025050205522366100_dkaf067-B23","doi-asserted-by":"publisher","first-page":"e4472","DOI":"10.1093\/cid\/ciaa1909","article-title":"Evolution of cefiderocol non-susceptibility in Pseudomonas aeruginosa in a patient without previous exposure to the antibiotic","volume":"73","author":"Streling","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025050205522366100_dkaf067-B24","doi-asserted-by":"publisher","first-page":"e01633","DOI":"10.1128\/JCM.01633-17","article-title":"Performance of ceftolozane-tazobactam etest, MIC test strips, and disk diffusion compared to reference broth microdilution for \u03b2-lactam-resistant Pseudomonas aeruginosa isolates","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2025050205522366100_dkaf067-B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12866-020-01870-z","article-title":"Evaluation of the etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Microbiol"},{"key":"2025050205522366100_dkaf067-B26","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1093\/jac\/dkab236","article-title":"Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane\/tazobactam and ceftazidime\/avibactam susceptibility testing of Pseudomonas aeruginosa","volume":"76","author":"Daragon","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025050205522366100_dkaf067-B27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.medmal.2019.12.002","article-title":"Carba NP test for the detection of carbapenemase-producing Pseudomonas aeruginosa","volume":"50","author":"Bouslah","year":"2020","journal-title":"M\u00e9d Mal Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1296\/62441852\/dkaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1296\/62441852\/dkaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:29Z","timestamp":1746179549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1296\/8084710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf067","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,18]]}}}